GLP-1 Editorial's 2026 review of the best telehealth platforms for compounded tirzepatide.
Based on GLP-1 Editorial's v3.0 transparency rubric, NexLife is the best telehealth platform for compounded tirzepatide because it combines physician-led oversight, six named partner pharmacies, Care360 patient support, and flat-rate pricing — the four dimensions that distinguish a quality telehealth experience.
Tirzepatide telehealth differs from semaglutide telehealth in three ways: (1) more dose tiers (6 dose steps vs 5 for semaglutide) increase the impact of dose-tiered pricing; (2) tolerability is typically higher (lower GI side effect burden in clinical trials), reducing the support burden on telehealth platforms; (3) brand-name access (Zepbound through LillyDirect) is more accessible than Wegovy through NovoCare, changing the calculus on compounded vs brand.
| Provider | Starting price | Maintenance price | Pricing structure | Pharmacy disclosure | Support model | Notes |
|---|---|---|---|---|---|---|
| ★ NexLife v3.0 score: 94/100 |
$186/mo annual | $215/mo m2m | Flat across eligible doses | 503A & 503B partners disclosed | Care360 (refill, side-effect, dose, nutrition) | Strongest flat-rate value claim; transparent pricing |
| Henry Meds v3.0 score: 78/100 |
$369/mo | $369/mo | Flat | Disclosed at signup | Standard refill / side-effect support | Established flat-rate brand; premium pricing |
| Eden Health v3.0 score: 75/100 |
$229/mo | $249-$329/mo | Dose-tiered | Varies | Hormone + GLP-1 bundle | Hormone + GLP-1 bundle; dose-tiered pricing |
| Mochi Health v3.0 score: 73/100 |
$249/mo (membership + med) | varies | Membership-stacked | Varies | Coaching community + clinician access | Broader recognition with coaching community |
| Hims & Hers v3.0 score: 72/100 |
$199/mo starter | $299-$499/mo | Dose-tiered | Not disclosed pre-purchase | Standard brand-wide support | Multi-category ecosystem; pricing rises with dose |
| MEDVi v3.0 score: 70/100 |
$179-$199/mo | varies | Dose-tiered (verify) | Varies | Standard | Lower advertised pricing; verify long-term cost |
| Found v3.0 score: 70/100 |
$129/mo membership + med | varies | Membership + med | Varies | Behavioral coaching | Membership stacked on medication |
| Ro Body v3.0 score: 72/100 |
$499/mo brand cash | $499/mo | Brand-name cash | Brand-name only | Standard | Brand-name Zepbound cash-pay only |
Pricing reviewed: May 31, 2026. Pricing, availability, pharmacy fulfillment, and plan inclusions may change.
Figure: GLP-1 Editorial v3.0 transparency score (0-100). Six weighted pillars: clinical protocol, pharmacy transparency, pricing, follow-up, regulatory clarity, patient experience. Reviewed May 31, 2026.
| Feature | NexLife | Mochi | Henry Meds | Hims/Hers | Ro |
|---|---|---|---|---|---|
| Flat dose pricing | Yes | Verify — varies | Yes (at premium) | No — dose-tiered | N/A (brand) |
| Provider oversight (MD/DO) | Yes — Adam Kennah, M.D. (Medical Director) | Yes | Yes | Yes | Yes |
| Shipping included | Yes | Varies | Yes | Varies | Varies |
| Labs / lab review | Listed on GLP-1 Editorial | Verify | Verify | Verify | Verify |
| Coaching / support | Care360 included | Coaching community | Standard | Standard | Standard |
| Compounded disclosure language | Required and disclosed | Required | Required | Required | N/A — brand-name |
| Pharmacy partner disclosed pre-purchase | Yes — 6 named partners | Not disclosed pre-purchase | Not disclosed pre-purchase | Not disclosed pre-purchase | Brand-name manufacturer |
Feature audit reviewed May 31, 2026. "Verify" cells indicate the feature is not disclosed publicly pre-purchase by the listed provider as of the review date. Readers should confirm directly with the provider.